Xueling Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xueling Zhang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Qin
Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Gaojie Fan
Louisiana State University, Baton Rouge, 70803
1 shared publication - Hanyue Xu
Sichuan University
1 shared publication HongSheng Wang
1 shared publication- Huajie Sui
Jiangxi University of Chinese Medicine, Nanchang, China
1 shared publication - Hui Zhang
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
1 shared publication
Latest Publications
- Open Access
- 14 May 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 6 (3) , 237-244
Overexpression of ACE2 ameliorates Aβ‐induced blood–brain barrier damage and angiogenesis by inhibiting NF‐κB/VEGF/VEGFR2 pathway
Background: Pathological angiogenesis and blood–brain barrier damage may play an important role in Alzheimer's disease (AD). ACE2 is mainly expressed on the surface of endothelial cells in brain. Recent studies have shown that the expression of ACE2 in AD is reduced, but its role in AD is still unclear.Method: We induced AD damage in endothelial cells using Aβ25‐35 and overexpressed ACE2 in bEend.3 cells through lentiviral transfection. We detected the effect of Aβ25‐35 on cell viability using the CCK‐8 assay and examined the effect of overexpressing ACE2 on angiogenesis using an angiogenesis assay. We used western blot and cell immunofluorescence to detect changes in the expression of the VEGF/VEGFR2 pathway, tight junction protein, and NF‐κB pathway.Results: Aβ25‐35 treatment significantly decreased the expression of ACE2 and reduced cell viability. ACE2 overexpression (1) reduced the number of branches and junctions in tube formation, (2) inhibited the activation of the VEGF/VEGFR2 pathway induced by Aβ25‐35, (3) increased the expression of TJPs, including ZO‐1 and claudin‐5, and (4) restored Aβ25‐35‐induced activation of the NF‐κB pathway.Conclusion: Overexpression of ACE2 can improve pathological angiogenesis and blood–brain barrier damage in AD models in vitro by inhibiting NF‐κB/VEGF/VEGFR2 pathway activity. ACE2 may therefore represent a therapeutic target for endothelial cell dysfunction in AD.
- 14 May 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 6 (3) , 237-244
Open AccessOverexpression of ACE2 ameliorates Aβ‐induced blood–brain barrier damage and angiogenesis by inhibiting NF‐κB/VEGF/VEGFR2 pathway
Background: Pathological angiogenesis and blood–brain barrier damage may play an important role in Alzheimer's disease (AD). ACE2 is mainly expressed on the surface of endothelial cells in brain. Recent studies have shown that the expression of ACE2 in AD is reduced, but its role in AD is still unclear.Method: We induced AD damage in endothelial cells using Aβ25‐35 and overexpressed ACE2 in bEend.3 cells through lentiviral transfection. We detected the effect of Aβ25‐35 on cell viability using the CCK‐8 assay and examined the effect of overexpressing ACE2 on angiogenesis using an angiogenesis assay. We used western blot and cell immunofluorescence to detect changes in the expression of the VEGF/VEGFR2 pathway, tight junction protein, and NF‐κB pathway.Results: Aβ25‐35 treatment significantly decreased the expression of ACE2 and reduced cell viability. ACE2 overexpression (1) reduced the number of branches and junctions in tube formation, (2) inhibited the activation of the VEGF/VEGFR2 pathway induced by Aβ25‐35, (3) increased the expression of TJPs, including ZO‐1 and claudin‐5, and (4) restored Aβ25‐35‐induced activation of the NF‐κB pathway.Conclusion: Overexpression of ACE2 can improve pathological angiogenesis and blood–brain barrier damage in AD models in vitro by inhibiting NF‐κB/VEGF/VEGFR2 pathway activity. ACE2 may therefore represent a therapeutic target for endothelial cell dysfunction in AD.
- Open Access
- 29 May 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Facial emotion recognition in adult with traumatic brain injury: a protocol for systematic review and meta-analysis
INPLASY202050109 Facial emotion recognition in adult with traumatic brain injury: a protocol for systematic review and meta-analysis Keywords: traumatic brain injury; facial emotion recognition; sy…
- 29 May 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessFacial emotion recognition in adult with traumatic brain injury: a protocol for systematic review and meta-analysis
INPLASY202050109 Facial emotion recognition in adult with traumatic brain injury: a protocol for systematic review and meta-analysis Keywords: traumatic brain injury; facial emotion recognition; sy…
- 26 September 2019
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 25 (21) , 2394-2403
Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies
Background: Maintaining the exposure of tacrolimus (Tac) after kidney transplantation (KT) must be necessary to prevent acute rejection (AR) and improve graft survival,but there is still no clear consensus on the optimal Tac target blood concentration and concentration-effect relationship is poorly defined.Methods: We conducted a dose-response meta-analysis to quantitatively assess the association between Tac blood concentration and (AR) or adverse effects after KT. A comprehensive search of PubMed, Embase and Cochrane library databases was conducted to find eligible studies up to 10th September 2018. Unpublished data from patients receiving KT in West China Hospital (Sichuan University, China) were also collected. Both twostage dose-response and one-stage dose-response meta-analysis models were used to improve the statistical power.Results: A total of 4967 individuals from 10 original studies and 1453 individuals from West China Hospital were eligible for the ultimate analysis. In the two-stage dose-response meta-analysis model, we observed a significant non-linear relationship between Tac blood concentration and AR (P < 0.001) with moderate heterogeneity (I2 = 46.0%, P = 0.08). Tac blood concentration at 8ng/ml was associated with the lowest risk of AR (RR: 0.26, 95%CI: 0.13 - 0.54) by reference to 2ng/ml. Tac concentration at 7.0 - 11.0 ng/ml reduced the risk of AR by at least 70%, 5-14 ng/ml by at least 60%, and 4.5 – 14 ng/ml at least 50%. In the one-stage dose-response model, we also found a strong non-linear relationship between Tac and AR (P < 0.001) with moderate heterogeneity (I2 = 41.2%, P = 0.10). Tac concentration of 7.5 ng/ml was associated with the lowest risk of AR (RR: 0.35, 95%CI: 0.16 - 0.77). The blood concentration at 5.5 - 9.5 ng/ml was associated with the reduced AR by at least 60% and 4.5 - 10.5 ng/ml by at least 50% by reference to 2 ng/ml.Conclusion: Maintaining Tac blood concentration at 5 - 9.5 ng/ml within the first year may prevent AR most effectively.
- 26 September 2019
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 25 (21) , 2394-2403
Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies
Background: Maintaining the exposure of tacrolimus (Tac) after kidney transplantation (KT) must be necessary to prevent acute rejection (AR) and improve graft survival,but there is still no clear consensus on the optimal Tac target blood concentration and concentration-effect relationship is poorly defined.Methods: We conducted a dose-response meta-analysis to quantitatively assess the association between Tac blood concentration and (AR) or adverse effects after KT. A comprehensive search of PubMed, Embase and Cochrane library databases was conducted to find eligible studies up to 10th September 2018. Unpublished data from patients receiving KT in West China Hospital (Sichuan University, China) were also collected. Both twostage dose-response and one-stage dose-response meta-analysis models were used to improve the statistical power.Results: A total of 4967 individuals from 10 original studies and 1453 individuals from West China Hospital were eligible for the ultimate analysis. In the two-stage dose-response meta-analysis model, we observed a significant non-linear relationship between Tac blood concentration and AR (P < 0.001) with moderate heterogeneity (I2 = 46.0%, P = 0.08). Tac blood concentration at 8ng/ml was associated with the lowest risk of AR (RR: 0.26, 95%CI: 0.13 - 0.54) by reference to 2ng/ml. Tac concentration at 7.0 - 11.0 ng/ml reduced the risk of AR by at least 70%, 5-14 ng/ml by at least 60%, and 4.5 – 14 ng/ml at least 50%. In the one-stage dose-response model, we also found a strong non-linear relationship between Tac and AR (P < 0.001) with moderate heterogeneity (I2 = 41.2%, P = 0.10). Tac concentration of 7.5 ng/ml was associated with the lowest risk of AR (RR: 0.35, 95%CI: 0.16 - 0.77). The blood concentration at 5.5 - 9.5 ng/ml was associated with the reduced AR by at least 60% and 4.5 - 10.5 ng/ml by at least 50% by reference to 2 ng/ml.Conclusion: Maintaining Tac blood concentration at 5 - 9.5 ng/ml within the first year may prevent AR most effectively.
- 17 August 2019
- Published by Springer Nature
- p. 113-120
Microexpression Recognition Training in Left-Behind Children in China
- 17 August 2019
- Published by Springer Nature
- p. 113-120
Microexpression Recognition Training in Left-Behind Children in China